ok-1238: Oklahoma Health Care Authority — Medical Providers-Fee for Service
Public comment closed .
Get alerted when the next rule lands
New rules open for comment on their own schedule. Pick how you want to hear about them — we email you when one appears.
Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.
Create a free account & build one →Summary
These revisions are necessary to avoid violation of federal law at 42 USC 1395w (Section 11403 of the Inflation Reduction Act of 2022). The proposed additions will align reimbursement for certain biosimilar products with the Medicare Part B fee schedule. The Inflation Reduction Act (2022) included a provision directing Medicare Part B to increase reimbursement for certain biosimilar products from Average Sales Price (ASP) + 6% to ASP + 8%. Based on CMS guidance, OHCA is amending policy to replace specific references to ASP + 6% with language indicating payment will match Medicare Part B’s fee schedule.
The agency’s own summary, as published.
Don't miss the comment window
One Click Politics alerts you on every deadline, hearing, and rule change.
See all rules with comments due soon →